Stockwatch: All that glisters is not gold
This article was originally published in Scrip
Reporting its first quarter 2011 financial results, Pfizer gave investors a hint of how it was dealing with ex-US generic competition to its blockbuster lipid-lowering drug, Lipitor before it has to face that challenge at home later this year.
You may also be interested in...
With the 38th J.P. Morgan Healthcare conference about to start in San Francisco, expectations in the investment community are naturally high. This is after a year when the NASDAQ Biotech Index approached its 2015 all-time high, fueled by the acquisitions of biotech companies by pharma companies.
Time is the least considered driver of asset valuations in life sciences – and may be a factor behind the low level of M&A deals so far this year. ICON’s Andy Smith provides some advice to the C-suite and business development managers on strategies to clarify the duration aspect in risk-sensitive transaction negotiations.
Mid-cap biotech companies Alexion and United Therapeutics both missed fourth-quarter sales expectations and although Intercept beat analysts' estimates with $13.4m in sales, does that justify a $3bn valuation?